^
    Back
    Association details:
    Biomarker:EGFR mutation
    Cancer:Non Small Cell Lung Cancer
    Drug Class:Immunotherapy +
    Angiogenesis inhibitor
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    Front Oncol
    Title:

    Immunotherapy strategies for EGFR-mutated advanced NSCLC after EGFR tyrosine-kinase inhibitors failure

    Published date:
    10/23/2023
    Excerpt:
    NSCLC patients with positive EGFR mutations after EGFR-TKIs failure received subsequent immunotherapy plus anti-angiogenesis and chemotherapy are likely to have more benefits in ORR, DCR and mPFS...
    Secondary therapy:
    Chemotherapy
    DOI:
    10.3389/fonc.2023.1265236
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Cancer Med
    Title:

    The efficacy and safety of immune checkpoint inhibitors for patients with EGFR-mutated non-small cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy: A systematic review and network meta-analysis

    Published date:
    08/16/2023
    Excerpt:
    ICIs+Chemo+Antiangio brings the greatest survival benefit in NSCLC patients with EGFR mutations who progressed on EGFR-TKI therapy, even for whom with baseline brain metastases.
    Secondary therapy:
    Chemotherapy
    DOI:
    https://doi.org/10.1002/cam4.6453
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Cancer Treat Rev
    Title:

    Immune checkpoint inhibitors in EGFR-mutant non-small cell lung cancer: A systematic review

    Published date:
    07/18/2023
    Excerpt:
    We performed a systematic review on efficacy of ICI-based strategies in EGFR-mutant NSCLC according to most updated evidence….the combination of ICI with antiangiogenic and chemotherapy showed promising results.
    Secondary therapy:
    Chemotherapy
    DOI:
    https://doi.org/10.1016/j.ctrv.2023.102602